AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Ascendis Pharma AS (NASDAQ:ASND)
230.83 USD
-0.320 0.138%Sponsored Reports
Loading...
| Previous Close (in USD) | 231.15 |
|---|---|
| Change | -0.320 0.138% |
| 52 W H/L (in USD) | 250.740/150.890 |
| EBITDA (in USD) | -131.415M |
| PE Ratio | -- |
| Volume | 908472 |
| Diluted Eps TTM | -4.45 |
| Total Assets (in USD) | 1302.015M |
|---|---|
| Total Liabilities (in USD) | 1464.767M |
| Revenue TTM (in USD) | 720.132M |
| Cash (in USD) | 615.779M |
| Market Cap (in USD) | 15,064.653 M |
| Revenue Per Share TTM | 11.882 |
| Gross Profit TTM (in USD) | 625.217M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Employees: 1189
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Jan Moller Mikkelsen | Pres, CEO, Member of Exec. Board & Exec. Director | 1960 |
| 2. | Mr. Michael Wolff Jensen L.L.M. | Sr. VP, Chief Legal Officer & Member of the Exec. Board | 1971 |
| 3. | Dr. Birgitte Volck M.D., Ph.D. | Sr. VP and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs | 1962 |
| 4. | Mr. Scott T. Smith | CFO, Sr. VP & Member of Exec. Board | 1974 |
| 5. | Ms. Lotte Sonderbjerg | Chief Admin. Officer, Sr. VP & Member of the Exec. Board | 1961 |
| 6. | Mr. Peter Rasmussen | VP of Fin. & Principal Accounting Officer | 1969 |
| 7. | Mr. Timothy J. Lee | Sr. Director of Investor Relations | NA |
| 8. | Mr. Flemming Steen Jensen | Sr. VP of Product Supply & Quality | 1961 |
| 9. | Dr. Kennett Sprogoe | Sr. VP and Head of Innovation & Research | 1979 |
| 10. | Dr. Jens Sigurd Okkels Ph.D. | Sr. VP of Product Devel. | 1961 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -204.258M | -373.241M | -474.144M | -577.817M | -383.944M |
| Minority Interest | - | - | - | - | - |
| Net Income | -219.034M | -378.084M | -481.447M | -583.194M | -383.577M |
| Selling General Administrative | 448.044M | 284.545M | 264.41M | 221.227M | 160.18M |
| Gross Profit | 588.531M | 319.383M | 222.323M | 39.037M | 4.255M |
| Reconciled Depreciation | 17.696M | 17.714M | 18.911M | 17.958M | 15.391M |
| Ebit | -130.893M | -307.737M | -430.079M | -573.675M | -439.673M |
| Ebitda | -113.895M | -290.023M | -411.168M | -556.04M | -423.668M |
| Depreciation And Amortization | 16.998M | 17.714M | 18.911M | 17.635M | 16.005M |
| Operating Income | -130.893M | -278.763M | -455.541M | -561.814M | -451.792M |
| Other Operating Expenses | 822.603M | 642.404M | 722.259M | 612.988M | 459.57M |
| Interest Expense | 77.464M | 65.504M | 44.065M | 50.487M | 3.911M |
| Tax Provision | 15.383M | 4.843M | 7.303M | 5.377M | -0.367M |
| Interest Income | 15.301M | 14.361M | 16.857M | 7.426M | 0.692M |
| Net Interest Income | -44.877M | -51.143M | -27.208M | -43.061M | -3.219M |
| Income Tax Expense | 14.776M | 4.843M | 7.303M | 5.377M | -0.367M |
| Total Revenue | 691.71M | 363.641M | 266.718M | 51.174M | 7.778M |
| Total Operating Expenses | 719.424M | 598.146M | 677.864M | 600.851M | 456.047M |
| Cost Of Revenue | 103.179M | 44.258M | 44.395M | 12.137M | 3.523M |
| Total Other Income Expense Net | -73.365M | -94.478M | -18.603M | -16.003M | 67.848M |
| Net Income From Continuing Ops | -228.034M | -378.084M | -481.447M | -583.194M | -383.577M |
| Net Income Applicable To Common Shares | - | - | - | -583.194M | -383.577M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 1302.015M | 1179.495M | 825.587M | 1089.738M | 1084.921M |
| Intangible Assets | 0.215M | 0.533M | 0.924M | 1.333M | 1.777M |
| Other Current Assets | 33.701M | 39.429M | 38.578M | 31.717M | 25.231M |
| Total Liab | 1464.767M | 1285.201M | 971.284M | 826.39M | 201.286M |
| Total Stockholder Equity | -162.752M | -105.706M | -145.697M | 263.348M | 883.635M |
| Other Current Liab | 487.05M | 317.775M | 76.194M | 44.818M | 31.343M |
| Common Stock | 8.318M | 8.149M | 7.749M | 7.675M | 7.646M |
| Capital Stock | 8.322M | 8.149M | 7.749M | 7.675M | 7.646M |
| Retained Earnings | -2699.238M | -2559.7M | -2278.973M | -1860.493M | -1413.855M |
| Good Will | 3.494M | 3.495M | 3.495M | 3.495M | 3.495M |
| Other Assets | - | - | - | 1.92M | 1.808M |
| Cash | 615.779M | 559.543M | 392.164M | 444.767M | 446.267M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 1068.936M | 907.863M | 197.344M | 171.271M | 100.356M |
| Current Deferred Revenue | 4.942M | 0.936M | 1.184M | - | 2.601M |
| Net Debt | 255.636M | 297.073M | 252.101M | 63.61M | -341.306M |
| Short Term Debt | 486.325M | 491.536M | 25.4M | 25.421M | 6.995M |
| Short Long Term Debt | 486.532M | 491.536M | 11.226M | 25.421M | - |
| Short Long Term Debt Total | 871.415M | 856.616M | 644.265M | 508.377M | 104.961M |
| Other Stockholder Equity | 2529.922M | 2444.062M | 2132.434M | 3.452M | 203.71M |
| Property Plant Equipment | - | - | - | 129.095M | 126.049M |
| Total Current Assets | 1108.513M | 1060.861M | 702.721M | 923.471M | 805.886M |
| Long Term Investments | 32.526M | 13.575M | 5.686M | 30.424M | 145.906M |
| Short Term Investments | - | 0M | 7.275M | 290.688M | 235.797M |
| Net Receivables | 157.629M | 166.28M | 55.773M | 25.626M | 23.186M |
| Long Term Debt | 385.254M | 365.08M | 534.246M | 482.956M | - |
| Inventory | 301.405M | 295.609M | 208.931M | 130.673M | 75.405M |
| Accounts Payable | 90.618M | 96.394M | 94.566M | 101.032M | 59.417M |
| Accumulated Other Comprehensive Income | -1.754M | 1.783M | -153.446M | 255.673M | 875.989M |
| Non Currrent Assets Other | - | 2.317M | 2.127M | 1.92M | 1.808M |
| Non Current Assets Total | 193.503M | 118.634M | 122.866M | 166.267M | 279.035M |
| Capital Lease Obligations | - | - | 98.793M | - | 104.961M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 0M | 6.876M | 279.026M | 61.732M | -86.345M |
| Total Cashflows From Investing Activities | -8.15M | 6.876M | - | 61.732M | -110.579M |
| Total Cash From Financing Activities | 34.894M | 443.929M | 134.292M | 396.773M | 351.387M |
| Net Income | -219.034M | -378.084M | -481.447M | -583.194M | -383.577M |
| Change In Cash | 122.646M | 167.379M | -52.603M | -1.5M | -138.25M |
| Begin Period Cash Flow | 493.133M | 392.164M | 444.767M | 446.267M | 584.517M |
| End Period Cash Flow | 615.779M | 559.543M | 392.164M | 444.767M | 446.267M |
| Total Cash From Operating Activities | 51.77M | -306.197M | -467.361M | -495.699M | -417.649M |
| Depreciation | 16.998M | 17.714M | 18.911M | 17.958M | 15.391M |
| Other Cashflows From Investing Activities | - | 0.95M | - | 9.535M | 9.535M |
| Dividends Paid | - | - | - | 5.06M | 33.142M |
| Change To Inventory | -5.686M | -86.678M | -78.258M | -55.268M | -75.405M |
| Sale Purchase Of Stock | -16.709M | 0M | -1.812M | -105.305M | -21.605M |
| Other Cashflows From Financing Activities | -10.946M | 11.223M | 8.474M | 5.153M | 44.679M |
| Capital Expenditures | 8.15M | 1.427M | 2.442M | 14.489M | 24.234M |
| Change In Working Capital | 68.159M | -107.157M | -99.786M | -18.617M | -48.914M |
| Other Non Cash Items | 182.439M | 60.975M | 20.998M | 18.597M | -67.012M |
| Free Cash Flow | 43.62M | -307.624M | -469.803M | -510.188M | -441.883M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | T. Rowe Price Capital Appreciation | 2 months ago | 2740767 |
| 2. | MFS Mid Cap Growth Equity | 5 months ago | 1279738 |
| 3. | MFS Mid Cap Growth A | 3 months ago | 1279738 |
| 4. | Capital Group Growth Fnd of Amer Comp | 5 months ago | 1209675 |
| 5. | American Funds Growth Fund of Amer A | 2 months ago | 1209675 |
| 6. | Vanguard Health Care Inv | 5 months ago | 1103469 |
| 7. | Franklin DynaTech A | 2 months ago | 1100000 |
| 8. | Franklin Innovation Composite | 5 months ago | 1000000 |
| 9. | Janus Henderson Mid Cap Growth MA | 8 months ago | 976876 |
| 10. | T. Rowe Price US Mid-Cap Growth Equity | 5 months ago | 784100 |
| 11. | T. Rowe Price Mid-Cap Growth | 2 months ago | 783400 |
| 12. | Janus Inst Mid Cap Growth CF | 5 months ago | 731867 |
| 13. | Fidelity Select Health Care | 3 months ago | 716000 |
| 14. | T. Rowe Price Health Sciences | 2 months ago | 699373 |
| 15. | Artisan Mid Cap Investor | 2 months ago | 678343 |
| 16. | Artisan U.S. Mid-Cap Growth | 2 months ago | 678343 |
| 17. | American Century Ultra® Inv | 2 months ago | 664000 |
| 18. | American Century US Premier Lg Cp Gr | 2 months ago | 664000 |
| 19. | Janus Henderson Enterprise D | 4 months ago | 614172 |
| 20. | American Funds SMALLCAP World A | 2 months ago | 579165 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Capital Research & Mgmt Co - Division 3 | 5 months ago | 3063943 |
| 2. | RA Capital Management, LLC | 5 months ago | 10281496 |
| 3. | Westfield Capital Management Company, L.P. | 5 months ago | 5185696 |
| 4. | venBio Select Advisor LLC | 5 months ago | 5111111 |
| 5. | HHG PLC | 8 months ago | 4323059 |
| 6. | FMR Inc | 5 months ago | 4153311 |
| 7. | Artisan Partners Limited Partnership | 5 months ago | 3225885 |
| 8. | T. Rowe Price Investment Management,Inc. | 5 months ago | 2747849 |
| 9. | Massachusetts Financial Services Company | 5 months ago | 1886393 |
| 10. | Wellington Management Company LLP | 5 months ago | 1762721 |
| 11. | T. Rowe Price Associates, Inc. | 8 months ago | 1726228 |
| 12. | Franklin Resources Inc | 8 months ago | 1589956 |
| 13. | American Century Companies Inc | 5 months ago | 1443141 |
| 14. | Perceptive Advisors LLC | 8 months ago | 1088501 |
| 15. | Amvescap Plc. | 8 months ago | 917903 |
| 16. | Principal Financial Group Inc | 8 months ago | 793677 |
| 17. | The Goldman Sachs Group Inc | 5 months ago | 596703 |
| 18. | JPMorgan Chase & Co | 8 months ago | 584792 |
| 19. | Ameriprise Financial Inc | 8 months ago | 562936 |
| 20. | Citadel Advisors Llc | 5 months ago | 519516 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...